Kafkas, SametKalkan, Nurdan YidizBolaman, ZahitKalkan, UzeyirOdabasi, Ali R. ZaYuksel, HasanBatun, Sabri2024-04-242024-04-2420061309-03991309-0380https://hdl.handle.net/11468/21429Objective: It is aimed that, to investigate the effect of estradiol valerate and dienogest combination, which is used as a hormone replacement therapy (HRT) regimen on hemostatic parameters and activated Protein C resistance in healthy postmenopausal women. Materials and Methods: Fifty seven women received HRT treatment in four month period. The placebo group consisted of 50 women. In the HRT group 10.5% (6/57), and in the placebo group 4% (2/50) were heterozigot of FV Leiden mutation. Hemostatic parameters were investigated in only non-mutation women, to avoid potential effects of FV Leiden mutation on activated Protein C. Results: Although these changes did not reach statistical significance, a comparison of hemostatic parameters for both groups showed that in the study group (receiving 2 mg EV/2 mg DNG) FV and Protein C levels were increased, and FVIII levels were decreased compared to the placebo group. There were also no significant differences in FVII and free Protein S levels. Multiple logistic regression analysis was performed to determine the association of (2 mg EV/2 mg DNG) treatment with FV, FVII, FVIII, Protein C, free Protein S and activated Protein C sensitivity rate. There was no significant effect of these independent variables on activated Protein C sensitivity rate (p>0.05). Discussion: Combination of estradiol valerate and dienogest has no effect on activated Protein C sensitivity ratios. Hormone replacement therapy does not cause acquired activated Protein C resistance (p>0.05).trinfo:eu-repo/semantics/closedAccessMenopauseHormone TherapyActivated Protein C ResistanceHaemostasisArticle74334341WOS:0004205772000112-s2.0-33846384588Q3N/A